The second Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland

Author:

Smith Sinéad M.1,Boyle Breida2,Buckley Martin3,Costigan Conor14,Doyle Maeve5,Farrell Richard6,Ismail M. Syafiq7,Kevans David18,Nugent Sean9,O’Connor Anthony14,O’Morain Colm1,Parihar Vikrant10,Ryan Cristín11,McNamara Deirdre14

Affiliation:

1. School of Medicine, Trinity College Dublin

2. Department of Clinical Microbiology, St. James’s Hospital, Dublin

3. Department of Gastroenterology, Mercy University Hospital, Cork

4. Department of Gastroenterology, Tallaght University Hospital, Dublin

5. Department of Microbiology, University Hospital Waterford, Waterford

6. Department of Gastroenterology, Connolly Hospital, RCSI, Dublin

7. Department of Gastroenterology, Cavan and Monaghan Hospital

8. Department of Gastroenterology, St. James’s Hospital, Dublin

9. Department of Gastroenterology, Whitfield Clinic, Waterford

10. Department of Gastroenterology, Letterkenny University Hospital

11. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland

Abstract

Background There has been an increase in resistance to many of the antimicrobials used to treat Helicobacter pylori (H. pylori) nationally and internationally. Primary clarithromycin resistance and dual clarithromycin and metronidazole resistance are high in Ireland. These trends call for an evaluation of best-practice management strategies. Objective The objective of this study was to revise the recommendations for the management of H. pylori infection in adult patients in the Irish healthcare setting. Methods The Irish H. pylori working group (IHPWG) was established in 2016 and reconvened in 2023 to evaluate the most up-to-date literature on H. pylori diagnosis, eradication rates and antimicrobial resistance. The ‘GRADE’ approach was then used to rate the quality of available evidence and grade the resulting recommendations. Results The Irish H. pylori working group agreed on 14 consensus statements. Key recommendations include (1) routine antimicrobial susceptibility testing to guide therapy is no longer recommended other than for clarithromycin susceptibility testing for first-line treatment (statements 6 and 9), (2) clarithromycin triple therapy should only be prescribed as first-line therapy in cases where clarithromycin susceptibility has been confirmed (statement 9), (3) bismuth quadruple therapy (proton pump inhibitor, bismuth, metronidazole, tetracycline) is the recommended first-line therapy if clarithromycin resistance is unknown or confirmed (statement 10), (4) bismuth quadruple therapy with a proton pump inhibitor, levofloxacin and amoxicillin is the recommended second-line treatment (statement 11) and (5) rifabutin amoxicillin triple therapy is the recommend rescue therapy (statement 12). Conclusion These recommendations are intended to provide the most relevant current best-practice guidelines for the management of H. pylori infection in adults in Ireland.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference106 articles.

1. Kyoto global consensus report on Helicobacter pylori gastritis.;Sugano;Gut,2015

2. Helicobacter pylori infection.;Malfertheiner;Nat Rev Dis Primers,2023

3. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.;Malfertheiner;Gut,2022

4. Shistosomes, liver flukes and Helicobacter pylori.;IARC Monogr Eval Carcinog Risks Hum,1994

5. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis.;Li;Lancet Gastroenterol Hepatol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3